Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic?

Nuclear Medicine and Biology

Volumn 32, Issue 7, 2005, Pages 657-662

  Eckelman, William C ^a   Rohatagi, Shashank ^b   Krohn, Kenneth A ^c   Vera, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sanyko Pharma Development   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Molecular imaging; Radioligands; Receptor binding radiotracer; Translational medicine

Indexed keywords

BLOOD PRESSURE REGULATION; COMBINATORIAL CHEMISTRY; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; MOLECULAR IMAGING; MOLECULAR PROBE; PATIENT CARE; REVIEW; RODENT; VALIDATION PROCESS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR PROBE TECHNIQUES; RADIONUCLIDE IMAGING;

EID: 27144466406     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2005.06.004     Document Type: Review

References (32)

1. C. Holden Lasker Awards. Geneticists knock out Lasker competition Science 293 5538 2001 2186
2. B.P. Zambrowicz, and A.T. Sands Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov 2 2003 38 51
3. B.P. Zambrowicz, G.A. Turner, and A.T. Sands Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry Curr Opin Pharmacol 3 2003 1 8
4. L. Bjermer, and Z. Diamant Current and emerging nonsteroidal anti-inflammatory therapies targeting specific mechanisms in asthma and allergy Treat Respir Med 3 4 2004 235 246
5. J.H. Ng, and L.L. Ilag Streamlining drug development: finding the right drug against the right target to treat the right disease Drug Discov Today 9 2004 59
6. A. Hopkins Are drugs discovered in the clinic or the laboratory? Drug Discov Today Targets 3 2004 173 175
7. F. Sams-Dodd Target-based drug discovery: is something wrong? Drug Discov Today Targets 10 2003 139 147
8. E. Balaban Eugenics and individual phenotypic variation: to what extent is biology a predictive science? Sci Context 11 1998 331 356
9. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, and J.M. Ford Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
10. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 3005 2004 399 401
11. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
12. A.D. Roses, D.K. Burns, S. Chissoe, L. Middleton, and P. St. Jean Disease-specific target selection: a critical first step down the right road Drug Discov Today 10 2005 177 189
13. Ehrlich P. On immunity, with special reference to cell-life (Croonian Lecture, Royal Society of London, 1990), reprinted in Collected Papers of Ehrlich P, vol 2, ed Himmelweit, New York, NY, Pergamon Press; 1957. p. 178-95.
14. J. Black A personal perspective on Dr. Paul Janssen J Med Chem 48 2005 1687 1688
15. R.G. Blasberg In vivo molecular-genetic imaging: multi-modality nuclear and optical combinations Nucl Med Biol 30 8 2003 879 888
16. I. Serganova, and R. Blasberg Reporter gene imaging: potential impact on therapy Nucl Med Biol 32 2005 763 780
17. B. Ravina, D. Eidelberg, J.E. Ahlskog, R.L. Albin, D.J. Brooks, and M. Carbon The role of radiotracer imaging in Parkinson disease Neurology 64 2 2005 208 215
18. K.A. Frey, R.A. Koeppe, M.R. Kilbourn, T.M. Vander Borght, R.L. Albin, and S. Gilman Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging Ann Neurol 40 6 1996 873 884
19. W.C. Eckelman The use of PET and knockout mice in the drug discovery process Drug Discov Today 8 9 2003 404 410
20. W.C. Eckelman Sensitivity of new radiopharmaceuticals Nucl Med Biol 25 3 1998 169 173
21. D.R. Vera, K.A. Krohn, P.O. Scheibe, and R.C. Stadalnik Identifiability analysis of an in vivo receptor-binding radiopharmacokinetic system IEEE Trans Biomed Eng 32 5 1985 312 322
22. G.A. Cowan Complexity: metaphors, models, and reality 1994 Addison-Wesley Publishing Co Reading (Mass)
23. P. Bak Self-organized criticality: a holistic view of nature 1994 Addison-Wesley Publishing Co Reading (Mass)
24. P.T. Saunders The organism as a dynamic system 1993 Addison-Wesley Publishing Co Reading (Mass)
25. D. Rodbard, and H.A. Feldman Theory of protein-ligand interaction B.W. O'Malley J. Hardman Methods Enzymol vol. 36 1975 Academic Press New York, NY 3 16
26. The mind, the brain, and complex adaptive systems 1993 Addison-Wesley Publishing Co Reading
27. R. Morphy, C. Kay, and Z. Rankovic From magic bullets to designed multiple ligands Drug Discov Today 9 15 2004 641 651
28. A. Carlsson, L.O. Hansson, and N. Waters Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications Life Sci 61 2 1997 75 94
29. A. Breier, T.P. Su, R. Saunders, R.E. Carson, B.S. Kolachana, and A. de Bartolomeis Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method Proc Natl Acad Sci U S A 94 6 1997 2569 2574
30. A. Breier, C.M. Adler, and N. Weisenfeld Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach Synapse 29 1998 142 147
31. W.C. Eckelman D.R. Vera Nucl Med Biol vol. 28 2001 475 608
32. W.C. Eckelman D.R. Vera Nucl Med Biol vol. 30 2003 895 973